2-[1-[5-(cyclohexyl-carbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid | 1024033-39-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-[1-[5-(cyclohexyl-carbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid
• 英文别名: 3-Piperidineacetic acid, 1-[5-[(cyclohexylamino)carbonyl]-6-(propylthio)-2-pyridinyl]-, (3S)-;3-Piperidineacetic acid, 1-[5-[(cyclohexylamino)carbonyl]-6-(propylthio)-2-pyridinyl]-, (3S)-；2-[1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]piperidin-3-yl]acetic acid
• CAS: 1024033-39-3
• 化学式: C₂₂H₃₃N₃O₃S
• 分子量: 419.588
• InChiKey: NCDZABJPWMBMIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• CHEMICAL COMPOUNDS
  申请人：McCoull William

  公开号：US20080269288A1

  公开（公告）日：2008-10-30

  Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are described.

  公式（I）的化合物：其中变量基团在内部定义；描述了它们在抑制11βHSD1中的应用，制备它们的过程以及包含它们的药物组合物。
• (S)-2-(1-(5-(CYCLOHEXYLCARBAMOYL)-6-(PROPYLTHIO)PYRIDIN-2-YL)PIPERIDIN-3-YL) ACETIC ACID FOR USE IN TREATING WOUNDS
  申请人：University of Leeds

  公开号：EP3821892A1

  公开（公告）日：2021-05-19

  The present specification relates to (S)-2-(1-(S-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid (AZD4017), or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of wounds, for example in diabetic patients. Methods of treatment and prophylaxis and the use of the compound in the preparation of a medicament for the treatment and prophylaxis of wounds are also provided.

  本说明书涉及(S)-2-(1-(S-(环己基氨基甲酰基)-6-(丙硫基)吡啶-2-基)哌啶-3-基)乙酸(AZD4017)或其药学上可接受的盐，用于治疗或预防伤口，例如糖尿病患者的伤口。此外，还提供了治疗和预防方法，以及该化合物在制备治疗和预防伤口的药物中的用途。
• AUTOMATED ASSESSMENT OF WOUND TISSUE
  申请人：Astrazeneca AB

  公开号：EP4002381A1

  公开（公告）日：2022-05-25

  A method of assessing a wound in a subject is provided. The method comprises obtaining one or more optical coherence tomography images of the wound and analysing the one or more optical coherence tomography images using a deep learning model that has been trained to classify pixels in an optical coherence tomography image of a wound between a plurality of classes comprising a plurality of classes associated with different types of wound tissue, thereby obtaining for each image analysed, an indication of the location of tissue likely to belong to each of the different types of wound tissue in the respective image.

  提供了一种评估受试者伤口的方法。该方法包括获取伤口的一个或多个光学相干断层扫描图像，并使用深度学习模型分析一个或多个光学相干断层扫描图像，该模型已被训练为在多个类别之间对伤口的光学相干断层扫描图像中的像素进行分类，这些类别包括与不同类型的伤口组织相关联的多个类别，从而获取所分析的每个图像中可能属于每个不同类型伤口组织的组织的位置指示。
• PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS
  申请人：AstraZeneca AB

  公开号：EP2086939B1

  公开（公告）日：2010-07-28
• Chemical compounds
  申请人：AstraZeneca AB

  公开号：EP2233480B1

  公开（公告）日：2013-05-29